Source: Nagoya UniversityA study led by Nagoya University Graduate School of Medicine in Japan has revealed a link between gut microbiota and Parkinson’s disease (PD).
Various physiological processes are heavily influenced by the microorganisms found in the gut, which are collectively known as gut microbiota.
Various physiological processes are heavily influenced by the microorganisms found in the gut, which are collectively known as gut microbiota.
In ideal conditions, gut microbiota produce SCFAs and polyamines, which maintain the intestinal barrier that prevents toxins entering the bloodstream.
“Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease” by Hiroshi Nishiwaki et al.
Summary: A new study reveals a link between gut bacteria and Parkinson’s disease (PD). Researchers found a decrease in genes responsible for synthesizing essential B vitamins in PD patients, which may weaken the intestinal barrier and lead to inflammation in the brain. This finding suggests that B vitamin supplementation could be a potential therapeutic avenue for PD.
Key Facts:
Reduced B vitamin-synthesizing bacteria in PD patients’ guts.
Weakened intestinal barrier due to B vitamin deficiency may lead to brain inflammation.
B vitamin supplementation could be a potential treatment for PD.
Source: Nagoya University
A study led by Nagoya University Graduate School of Medicine in Japan has revealed a link between gut microbiota and Parkinson’s disease (PD). The researchers found a reduction in the gut bacteria of genes responsible for synthesizing the essential B vitamins B2 and B7.
They also identified a relationship between the lack of these genes and low levels of agents that help maintain the integrity of the intestinal barrier. This barrier prevents toxins from entering the bloodstream, which causes the inflammation seen in PD.
Their findings, published in npj Parkinson’s Disease, suggest that treatment with B vitamins to address these deficiencies can be used to treat PD.
Various physiological processes are heavily influenced by the microorganisms found in the gut, which are collectively known as gut microbiota. Credit: Neuroscience News
PD is characterized by a variety of physical symptoms that hinder daily activities and mobility, such as shaking, slow movement, stiffness, and balance problems. While the frequency of PD may vary between different populations, it is estimated to affect approximately 1-2% of individuals aged 55 years or older.
Various physiological processes are heavily influenced by the microorganisms found in the gut, which are collectively known as gut microbiota. In ideal conditions, gut microbiota produce SCFAs and polyamines, which maintain the intestinal barrier that prevents toxins entering the bloodstream.
Toxins in the blood can be carried to the brain where they cause inflammation and affect neurotransmission processes that are critical for maintaining mental health.
To better understand the relationship between the microbial characteristics of the gut in PD, Hiroshi Nishiwaki and Jun Ueyama from the Nagoya University Graduate School of Medicine conducted a metanalysis of stool samples from patients with PD from Japan, the United States, Germany, China, and Taiwan.
They used shotgun sequencing, a technique that sequences all genetic material in a sample. This is an invaluable tool because it offers researchers a better understanding of the microbial community and genetic makeup of the sample.
They observed a decrease in the bacterial genes responsible for the synthesizing of riboflavin (vitamin B2) and biotin (vitamin B7) in patients diagnosed with PD. Riboflavin and biotin, derived from both food and gut microbiota, have anti-inflammatory properties, which may counteract the neuroinflammation seen in diseases like PD.
B vitamins play crucial roles in the metabolic processes that influence the production and functions of short-chain fatty acids (SCFAs) and polyamines, two agents that help maintain the integrity of the intestinal barrier, preventing toxins entering the bloodstream. An examination of fecal metabolites revealed decreases of both in patients with PD.
The findings indicate a potential explanation for the progression of PD. “Deficiencies in polyamines and SCFAs could lead to thinning of the intestinal mucus layer, increasing intestinal permeability, both of which have been observed in PD,” Nishiwaki explained.
“This higher permeability exposes nerves to toxins, contributing to abnormal aggregation of alpha-synuclein, activating the immune cells in the brain, and leading to long-term inflammation.”
He added, “Supplementation therapy targeting riboflavin and biotin holds promise as a potential therapeutic avenue for alleviating PD symptoms and slowing disease progression.”
The results of the study highlight the importance of understanding the complex relationship among gut microbiota, metabolic pathways, and neurodegeneration. In the coming years, therapy could potentially be customized based on the unique microbiome profile of each patient. By altering bacterial levels in the microbiome, doctors can potentially delay the onset of symptoms associated with diseases like PD.
“We could perform gut microbiota analysis on patients or conduct fecal metabolite analysis,” Nishiwaki said.
“Using these findings, we could identify individuals with specific deficiencies and administer oral riboflavin and biotin supplements to those with decreased levels, potentially creating an effective treatment.”
About this Parkinson’s disease research news
Author: Matthew Coslett
Source: Nagoya University
Contact: Matthew Coslett – Nagoya University
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease” by Hiroshi Nishiwaki et al. npj Parkinson’s Disease
Abstract
Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease
We aimed to identify gut microbial features in Parkinson’s disease (PD) across countries by meta-analyzing our fecal shotgun sequencing dataset of 94 PD patients and 73 controls in Japan with five previously reported datasets from USA, Germany, China1, China2, and Taiwan. GC-MS and LC-MS/MS assays were established to quantify fecal short-chain fatty acids (SCFAs) and fecal polyamines, respectively. α-Diversity was increased in PD across six datasets.
Taxonomic analysis showed that species Akkermansia muciniphila was increased in PD, while species Roseburia intestinalis and Faecalibacterium prausnitzii were decreased in PD.
Pathway analysis showed that genes in the biosyntheses of riboflavin and biotin were markedly decreased in PD after adjusting for confounding factors. Five out of six categories in carbohydrate-active enzymes (CAZymes) were decreased in PD.
Metabolomic analysis of our fecal samples revealed that fecal SCFAs and polyamines were significantly decreased in PD. Genes in the riboflavin and biotin biosyntheses were positively correlated with the fecal concentrations of SCFAs and polyamines.
Bacteria that accounted for the decreased riboflavin biosynthesis in Japan, the USA, and Germany were different from those in China1, China2, and Taiwan. Similarly, different bacteria accounted for decreased biotin biosynthesis in the two country groups.
We postulate that decreased SCFAs and polyamines reduce the intestinal mucus layer, which subsequently facilitates the formation of abnormal α-synuclein fibrils in the intestinal neural plexus in PD, and also cause neuroinflammation in PD.
